LUCD

Lucid Diagnostics' stock price has been impacted by equity offerings, earnings reports, reimbursement milestones, conference participations, and concerns about its ability to continue as a going concern. In April 2026, Lucid Diagnostics closed an $18 million underwritten offering of common stock. The company reported net losses of $58.0 million in 2025 and $45.5 million in 2024. Lucid Diagnostics has made progress in securing reimbursement for its EsoGuard test, including a U.S. Department of Veterans Affairs contract and initial commercial coverage from Highmark Blue Cross Blue Shield in New York. In its March 2026 annual report, Lucid Diagnostics stated there is substantial doubt about its ability to continue as a going concern beyond March 2027 without additional capital. The stock has traded between $0.95 and $1.70 over the past 52 weeks, and as of May 7, 2026, the share price was $1.05.